GlassScriptPhysician profile
Alicia D Haslauer
NPI 1174832612
$14,296.32
in general payments reported to CMS, 2019-2025
28 companies · $7,932 in 2025
The $7,932 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,243 · 2022: $1,604 · 2023: $1,928 · 2024: $1,589 · 2025: $7,932.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,685 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,100 · Travel and Lodging: $474 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,684.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,100.00 |
| Travel and Lodging | $474.10 |
| Education | $190.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $6,232.10 | 2021-2025 | Nemluvio, Aklief |
| Genzyme Corporation | $1,859.76 | 2021-2025 | |
| Abbvie INC. | $1,177.52 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $842.99 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $823.75 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $534.22 | 2021-2025 | |
| Incyte Corporation | $349.91 | 2021-2025 | Opzelura |
| Janssen Biotech, INC. | $323.01 | 2022-2025 | Tremfya |
| Ucb, INC. | $309.66 | 2021-2024 | Bimzelx, Cimzia |
| Pfizer INC. | $301.98 | 2021-2025 | |
| Amgen INC. | $292.87 | 2021-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $198.25 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $193.36 | 2021-2024 | Adbry |
| Sanofi-Aventis U.S. LLC | $171.99 | 2022-2024 | |
| Dermavant Sciences, INC. | $160.79 | 2023-2024 | Vtama |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.33 | 2021-2023 | Arazlo, Jublia |
| Organon LLC | $88.68 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $82.37 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $47.34 | 2021-2023 | Absorica Ld, Winlevi |
| Krystal Biotech INC | $40.33 | 2023 | Vyjuvek |
| Lnhc, INC | $24.53 | 2025 | Zelsuvmi |
| Allergan, INC. | $23.84 | 2022 | |
| Nabriva Therapeutics, Plc | $22.24 | 2022 | |
| Mallinckrodt Hospital Products INC. | $20.31 | 2024 | Acthar |
| Dermira, INC. | $19.53 | 2021 | |
| Verrica Pharmaceuticals INC. | $16.20 | 2023 | Ycanth |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.48 | 2023 | |
| Medimetriks Pharmaceuticals, INC. | $14.98 | 2025 | Clindacin Etz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Haslauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.